Researchers tracked 11만6064 adults aged 40 and older who were newly diagnosed with type 2 diabetes between 2005 and 2019, alongside a control group of 28만6599 individuals without diabetes, over a maximum follow-up period of 15 years.
Pancreatic Cancer Risk Rises with Diabetes Treatment Intensity
Pancreatic cancer remains exceptionally lethal, with 80 to 90 percent of patients diagnosed at an advanced stage where surgical resection is impossible. Even among patients eligible for surgery, the five-year survival rate lingers at approximately 20 percent. Because diabetes frequently acts as an early warning sign—present in roughly half of all pancreatic cancer patients prior to their tumor diagnosis—identifying high-risk individuals before symptoms manifest is critical.
To determine how baseline disease severity impacts malignancy risk, the research team categorized new diabetes patients based on their initial treatment requirements: an unmedicated group of 8만1644 individuals, an oral hypoglycemic agent group of 2만7876 individuals, and an insulin injection group of 6,544 individuals.
Compared to the non-diabetic control group, the risk of developing pancreatic cancer climbed alongside initial treatment intensity. The unmedicated group experienced a 3.01-fold higher risk, the oral medication group faced a 4.32-fold increase, and the insulin group showed a 5.6-fold surge. These associations intensified among patients diagnosed with pancreatic cancer within three years of their diabetes diagnosis, jumping to 4.75-fold for the unmedicated group, 9.44-fold for the oral medication group, and 10.73-fold for the insulin group.
Rapid Disease Progression Amplifies Malignancy Threat
The study also evaluated how changes in disease management during the first six months following a diabetes diagnosis affected subsequent cancer risk. Patients who required escalating treatment—such as adding medications or transitioning to insulin injections—faced significantly higher hazard ratios than those whose treatment intensity remained stable.
Patients who started with no medication but required the initiation of drug therapy within six months experienced a 6.50-fold increase in pancreatic cancer risk compared to healthy controls. That risk exceeded the 3.67-fold risk observed in patients who started on oral medications and maintained a stable regimen without escalation. Most notably, individuals who began on oral pills but required insulin therapy within six months saw their pancreatic cancer risk spike by 26.54-fold compared to the control cohort.
Despite the steep hazard ratios associated with rapid clinical deterioration, the absolute risk of pancreatic cancer among new-onset diabetes patients remains low, staying under 1 to 2 percent. Consequently, researchers emphasize that patients should avoid undue alarm while acknowledging the need for heightened clinical vigilance.
He added that because the absolute incidence of pancreatic cancer among new diabetes patients remains under 2 percent, clinical care teams must construct precise surveillance systems combining clinical symptoms, risk prediction models, and biomarkers.
>